Share This Page
Drugs in ATC Class N01BB
✉ Email this page to a colleague
Drugs in ATC Class: N01BB - Amides
| Tradename | Generic Name |
|---|---|
| BUPIVACAINE LIPOSOME | bupivacaine |
| EXPAREL | bupivacaine |
| POSIMIR | bupivacaine |
| XARACOLL | bupivacaine hydrochloride |
| >Tradename | >Generic Name |
N01BB Market Analysis and Financial Projection
The ATC Class N01BB encompasses amide-type local anesthetics, including lidocaine, bupivacaine, and prilocaine, which are critical in pain management for surgical and therapeutic procedures. This analysis integrates market dynamics and patent trends shaping this pharmaceutical segment.
Market Dynamics
The global local anesthesia drugs market was valued at $4.01 billion in 2023, with projections to grow at a CAGR of 3.6%–6.4% through 2030–2031, reaching up to $6.22 billion[14][18][19]. Key drivers include:
- Rising surgical volumes: Over 2.3 million cosmetic procedures annually in the U.S. and increasing caesarean sections globally[18][19].
- Aging populations: By 2050, 22% of the global population will be over 60, amplifying demand for surgical interventions[19].
- Advancements in drug delivery: Innovations like ultrasound-guided techniques and micellar formulations enhance precision and reduce toxicity[16][18].
Regional Insights:
- North America dominates due to high healthcare spending and surgical adoption[14][19].
- Asia-Pacific is the fastest-growing market, driven by expanding healthcare infrastructure and industrial sectors in China and India[5][18].
Patent Landscape
The N01BB amides sector features active innovation, focusing on prolonged efficacy and safety:
-
Formulation Patents:
- Micellar delivery systems: Block copolymers (e.g., mPEG-poly(caprylic acid)) solubilize lidocaine, enabling lower doses and reduced systemic toxicity[16].
- Combination therapies: Patents like US6326020B1 combine tetrodotoxin with amides for prolonged nerve blockade[11].
-
Key Players and Strategies:
- Bupivacaine hydrochloride has 83 international patents, with generic versions supplied by 22 manufacturers[17].
- Companies like Adeia and TSMC (in adjacent industries) exemplify aggressive IP licensing and hybrid bonding tech, mirroring trends in pharma patent strategies[9][12].
-
Legal and Regulatory Developments:
- Patent disputes, such as CRISPR-Cas9 conflicts between Broad Institute and UC, highlight the competitive IP environment[9].
- FDA approvals for formulations like Propoven 2% during COVID-19 underscore adaptive regulatory responses[8].
Challenges and Opportunities
- Safety concerns: Methemoglobinemia risks with prilocaine drive demand for alternatives like lidocaine micelles[16].
- Generic competition: Expiring patents (e.g., bupivacaine) intensify price pressures, prompting innovation in delivery systems[17].
- Emerging applications: Expansion into photonics, MEMS, and chronic pain management opens new revenue streams[12][16].
Key Players
Leading companies include Teva, Aspen Holdings, Pacira Pharmaceuticals, and Fresenius Kabi, focusing on R&D for novel adjuvants and sustained-release formulations[14][19].
In summary, the N01BB amides market thrives on surgical demand and innovation, with patent strategies emphasizing safer, longer-acting formulations. Regional growth in Asia-Pacific and evolving IP landscapes will shape future competitiveness.
<blockquote>
"Advancements in drug delivery systems, such as micellar formulations, are revolutionizing local anesthesia by enhancing efficacy while mitigating systemic risks." – Based on patent WO2020109254A1[16].
</blockquote> Key Takeaways
- Market growth is driven by aging populations and surgical innovations.
- Patent filings prioritize drug delivery and combination therapies.
- Asia-Pacific emerges as a high-growth region due to healthcare expansion.
FAQs
-
What are common drugs in ATC Class N01BB?
Lidocaine, bupivacaine, and prilocaine are widely used for local anesthesia[2][13]. -
How do micellar formulations improve safety?
They reduce peak plasma levels, lowering toxicity risks[16]. -
Which region leads in local anesthesia drug consumption?
North America, due to high surgical volumes and advanced healthcare[14][19]. -
What patents protect bupivacaine?
Over 80 international patents, with key filings in the U.S. and Europe[17]. -
What trends are shaping the patent landscape?
Focus on hybrid technologies and licensing strategies, as seen in semiconductors and CRISPR[9][12].
References
- https://www.marketsandmarkets.com/Market-Reports/fatty-amides-market-54171685.html
- https://atcddd.fhi.no/atc_ddd_index/?code=N01BB51
- https://www.drugpatentwatch.com/p/patent/5466700
- https://atcddd.fhi.no/atc_ddd_index/?code=N01B
- https://www.stratviewresearch.com/3506/fatty-amides-market.html
- https://www.doc-developpement-durable.org/file/sante-hygiene-medecine/guides-medicaux/the%20selection%20and%20use%20of%20essential%20medicines%202009%20-%20WHO.pdf
- https://patents.google.com/patent/US2844629A/en
- https://www.mordorintelligence.com/industry-reports/global-anesthesia-drugs-market-industry
- https://www.ipstudies.ch/2020/10/2020-crispr-patent-landscape-where-do-we-stand/
- https://www.globenewswire.com/news-release/2016/04/05/825802/33097/en/Global-Fatty-Amides-Market-Erucamide-Oleamide-Stearamide-and-Behenamide-is-Expected-to-be-Valued-at-US-319-7-Mn-by-2022.html
- https://patents.google.com/patent/US6326020B1/en
- https://www.knowmade.com/patent-analytics-services/patent-report/semiconductor-patent-landscape/semiconductor-advanced-packaging-patent-landscape/hybrid-bonding-patent-landscape-analysis-2024/
- https://atcddd.fhi.no/atc_ddd_index/?showdescription=yes&code=N01BB
- https://www.alliedmarketresearch.com/local-anesthesia-drugs-market-A31886
- https://patents.google.com/patent/US6482983B1/en
- https://patents.google.com/patent/WO2020109254A1/en
- https://www.drugpatentwatch.com/p/generic-api/BUPIVACAINE+HYDROCHLORIDE
- https://www.mordorintelligence.com/industry-reports/local-anesthesia-drugs-market
- https://www.grandviewresearch.com/industry-analysis/local-anesthesia-drugs-market
More… ↓
